Does an implantable cardioverter-defibrillator prevent sudden cardiac death and improve survival in patients with cardiac amyloidosis?
This narrative review summarizes current evidence on arrhythmic risk stratification and the unclear role of ICDs for primary prevention of sudden cardiac death in patients with cardiac amyloidosis.
Cardiac amyloidosis (CA) is considered to be associated with an increased risk of sudden cardiac death (SCD) due to ventricular tachyarrhythmias and electromechanical dissociation. However, current arrhythmic risk stratification and the role of an implantable cardioverter-defibrillator (ICD) for primary prevention of SCD remains unclear. This article provides a narrative review of the literature on electrophysiological abnormalities in the context of ventricular arrhythmias in patients with CA and the role of ICD in terms of survival benefit in this group of patients.
Liżewska-Springer et al. (Sun,) studied this question.